<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101465400</journal-id>
<journal-id journal-id-type="pubmed-jr-id">34171</journal-id>
<journal-id journal-id-type="nlm-ta">Sci Signal</journal-id>
<journal-id journal-id-type="iso-abbrev">Sci Signal</journal-id>
<journal-title-group>
<journal-title>Science signaling</journal-title>
</journal-title-group>
<issn pub-type="ppub">1945-0877</issn>
<issn pub-type="epub">1937-9145</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27273096</article-id>
<article-id pub-id-type="pmc">5274719</article-id>
<article-id pub-id-type="doi">10.1126/scisignal.aaf6060</article-id>
<article-id pub-id-type="manuscript">NIHMS841614</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Augmented noncanonical BMP type II receptor signaling mediates the synaptic abnormality of fragile X syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kashima</surname>
<given-names>Risa</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roy</surname>
<given-names>Sougata</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ascano</surname>
<given-names>Manuel</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martinez-Cerdeno</surname>
<given-names>Veronica</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ariza-Torres</surname>
<given-names>Jeanelle</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Sunghwan</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Louie</surname>
<given-names>Justin</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lu</surname>
<given-names>Yao</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leyton</surname>
<given-names>Patricio</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bloch</surname>
<given-names>Kenneth D.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kornberg</surname>
<given-names>Thomas B.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Paul J.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Randi</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lagna</surname>
<given-names>Giorgio</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hata</surname>
<given-names>Akiko</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="cor1">†</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA 94143, USA</aff>
<aff id="A2"><label>2</label>Department of Biochemistry, Vanderbilt University, Nashville, TN 37232, USA</aff>
<aff id="A3"><label>3</label>Institute for Pediatric Regenerative Medicine, Department of Pathology, University of California, Davis, Davis, CA 95817, USA</aff>
<aff id="A4"><label>4</label>MIND (Medical Investigation of Neurodevelopmental Disorders) Institute, University of California, Davis, Davis, CA 95817, USA</aff>
<aff id="A5"><label>5</label>Anesthesia and Critical Care, Massachusetts General Hospital, Boston, MA 02114, USA</aff>
<aff id="A6"><label>6</label>Department of Biochemistry and Molecular Medicine, University of California, Davis, Davis, CA 95817, USA</aff>
<author-notes>
<corresp id="cor1"><label>†</label>Corresponding author. <email>akiko.hata@ucsf.edu</email></corresp>
<fn id="FN1">
<label>*</label>
<p id="P1">Deceased.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>12</day>
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>07</day>
<month>6</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<day>07</day>
<month>6</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>29</day>
<month>1</month>
<year>2017</year>
</pub-date>
<volume>9</volume>
<issue>431</issue>
<fpage>ra58</fpage>
<lpage>ra58</lpage>
<!--elocation-id from pubmed: 10.1126/scisignal.aaf6060-->
<permissions>
<license license-type="permissions-link">
<license-p><bold>Permissions</bold> Obtain information about reproducing this article: <ext-link ext-link-type="uri" xlink:href="http://www.sciencemag.org/about/permissions.dtl">http://www.sciencemag.org/about/permissions.dtl</ext-link></license-p>
</license>
</permissions>
<abstract>
<p id="P2">Epigenetic silencing of <italic>fragile X mental retardation 1</italic> (<italic>FMR1</italic>) causes fragile X syndrome (FXS), a common inherited form of intellectual disability and autism. FXS correlates with abnormal synapse and dendritic spine development, but the molecular link between the absence of the <italic>FMR1</italic> product FMRP, an RNA binding protein, and the neuropathology is unclear. We found that the messenger RNA encoding bone morphogenetic protein type II receptor (BMPR2) is a target of FMRP. Depletion of FMRP increased BMPR2 abundance, especially that of the full-length isoform that bound and activated LIM domain kinase 1 (LIMK1), a component of the noncanonical BMP signal transduction pathway that stimulates actin reorganization to promote neurite outgrowth and synapse formation. Heterozygosity for <italic>BMPR2</italic> rescued the morphological abnormalities in neurons both in <italic>Drosophila</italic> and in mouse models of FXS, as did the postnatal pharmacological inhibition of LIMK1 activity. Compared with postmortem prefrontal cortex tissue from healthy subjects, the amount of full-length BMPR2 and of a marker of LIMK1 activity was increased in this brain region from FXS patients. These findings suggest that increased BMPR2 signal transduction is linked to FXS and that the BMPR2-LIMK1 pathway is a putative therapeutic target in patients with FXS and possibly other forms of autism.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>